STCube

STCube Depreciation & Amortization

The Depreciation & Amortization of STCube (052020.KQ) as of Oct 23, 2026 is 1.11 B KRW. In the previous year, Depreciation & Amortization was 918.08 M KRW — a change of 20.88% (higher).

Depreciation & Amortization

1.11 BKRW

YoY

20.88%

Last updated:

Depreciation & Amortization of STCube is 2024 1.11 B KRW. Depreciation & Amortization of STCube was 2023 918.08 M KRW. It decreases by 20.88% higher compared to the previous year.

The STCube Depreciation & Amortization history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Depreciation & Amortization
Date
Depreciation & Amortization
Jan 1, 2017
554.00 M KRW
Jan 1, 2018
65.00 M KRW
Jan 1, 2019
1.14 B KRW
Jan 1, 2020
634.28 M KRW
Jan 1, 2021
648.63 M KRW
Jan 1, 2022
807.50 M KRW
Jan 1, 2023
918.08 M KRW
Jan 1, 2024
1.11 B KRW
The STCube Depreciation & Amortization history
YEARDepreciation & AmortizationYoY
1.11 BKRW+20.88%
918.08 MKRW+13.69%
807.50 MKRW+24.49%
648.63 MKRW+2.26%
634.28 MKRW-44.56%
1.14 BKRW+1,660.00%
65.00 MKRW-88.27%
554.00 MKRW+194.68%
188.00 MKRW+16.77%
161.00 MKRW-62.82%
433.00 MKRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

STCube Stock analysis

What does STCube do? STCube Inc. generates revenue through its two business segments. The IT segment distributes CCTV lenses and related components, targeting businesses requiring security solutions. The BT segment develops and licenses immunomodulatory anticancer drug therapeutic candidates, selling to pharmaceutical companies and research institutions. Both segments operate under the company's brand, leveraging its IT and biotechnology expertise. The IT segment focuses on closed-circuit television lens distribution, serving commercial and industrial clients seeking reliable security infrastructure. The BT segment's drug development and licensing activities cater to the pharmaceutical industry, providing innovative therapeutic candidates for cancer treatment. These offerings align with STCube's dual expertise in technology and biotechnology. STCube's revenue streams are derived from product distribution in the IT sector and licensing agreements in the biotechnology sector. The company's clients include businesses needing CCTV components and pharmaceutical firms interested in anticancer drug development. This dual approach allows STCube to serve distinct market segments with specialized solutions. STCube is one of the most popular companies on Eulerpool.

Frequently Asked Questions about STCube stock

Depreciation & Amortization of STCube is 1.11 B KRW in 2024.

Depreciation & Amortization of STCube changed from 918.08 M KRW to 1.11 B KRW, representing a 20.88% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Depreciation & Amortization STCube since 2006 – with annual values, charts, and detailed analysis.

Depreciation & Amortization represents the allocation of the cost of tangible and intangible assets over their useful lives.

Depreciation & Amortization's KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Depreciation & Amortization's STCube historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — STCube

All Key Metrics — STCube